Management of cardiovascular disease in patients with diabetes: The 2008 Canadian Diabetes Association guidelines

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 9, 2008, Pages 920-926

  Bhattacharyya, Onil K ^a,b   Shah, Baiju R ^b,c   Booth, Gillian L ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHECKLIST; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GOLD STANDARD; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KINESIOTHERAPY; LIPID BLOOD LEVEL; LOW DRUG DOSE; MEDICAL SOCIETY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SMOKING;

EID: 54349095358     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080554     Document Type: Review

References (53)

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(suppl 1):S1-201. Available: www.diabetes.ca/for-professionals/resources/ 2008-cpg/
2. Booth GL, Kapral MK, Fung K, et al. Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care 2006;29:32-7.
3. National Institute for Clinical Excellence. The guideline development process: an overview for stakeholders, public and the NHS (3rd ed). London (UK): The Institute; 2007. Available: www.nice.org.uk/media/830/B9/ GuidelinesManualDevelopmentProcess.pdf (accessed 2008 Sep 6).
4. Australian Centre for Diabetes Strategies. Introduction and overview of the guideline development process. In: National evidence based guidelines for the management of type 2 diabetes mellitus. Sydney (Australia): National Health and Medical Research Council; 2005. Available: www.nhmrc.gov.au/ publications/synopses/_files/di7.pdf (accessed 2008 Sep 6).
5. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41.
6. Van Horn L, McCoin M, Kris-Etherton PM, et al. The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 2008;108:287-331.
7. Chan BT, Klomp H, Castagnette P. Quality of diabetes management in Saskatchewan. Saskatoon (SK): Health Quality Council; 2006.
8. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
9. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
10. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27:(suppl 2). Available: www.diabetes.ca/cpg2003/downloads/cpgcomplete.pdf (accessed 2008 Sep 6).
11. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
12. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
13. Woolf SH, Grol R, Hutchinson A, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999;318:527-30.
14. Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36.
15. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
16. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
17. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268:1292-300.
18. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
19. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-51.
20. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 1998;352:837-53.
21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
22. Schmittdiel J, Vijan S, Fireman B, et al. Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care 2007;45:315-21.
23. 2008 CHEP recommendations for the management of hypertension. Canadian Hypertension Education Program (CHEP); 2008. Available: hypertension.ca/chep/wp- content/uploads/2008/03/2008-chepspiral-booklet-final_jan28.pdf (accessed 2008 Sep 6).
24. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9.
25. Leenen FH, Dumais J, McInnis NH, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178:1441-9.
26. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-7.
27. Bremner AD. Antihypertensive medication and quality of life - Silent treatment of a silent killer? Cardiovasc Drugs Ther 2002;16:353-64.
28. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
29. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291:1342-9.
30. Verberk WJ, Kroon AA, Kessels AG, et al. Home blood pressure measurement: a systematic review. J Am Coll Cardiol 2005;46:743-51.
31. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
32. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Dyslipidemia in adults with diabetes. Can J Diabetes 2006;30:230-40. Available: www.diabetes.ca/files/CJDSep06Lipids.pdf (accessed 2008 Sep 6).
33. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43.
34. Zhou Z, Rahme E, Abrahamowicz M, et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005;172:1187-94.
35. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52-60C.
36. Statin safety: a perspective. Bandolier 2006;147. Available: www.medicine.ox.ac.uk/bandolier/band147/b147-3.html (accessed 2008 Sep 6).
37. Mitka M. Contradictory findings ignite questions about blood glucose targets in diabetes. JAMA 2008;299:1413-5.
38. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
39. Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007;335:132.
40. Heller SR. Self monitoring of blood glucose in type 2 diabetes. BMJ 2007;335:105-6.
41. O'Kane MJ, Bunting B, Copeland M, et al. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008;336:1174-7.
42. 2005/06 report card for the Ontario Drug Benefit Program. Toronto (ON): Ministry of Health and Long Term Care; 2008. Available: www.health.gov.on.ca/ english/public/pub/ministry_reports/odb_report05/odb_rep_05_06.pdf (accessed 2008 Sep 6).
43. Hu G, Jousilahti P, Barengo NC, et al. Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes Care 2005;28:799-805.
44. Hu FB, Stampfer MJ, Solomon C, et al. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 2001;134:96-105.
45. Gregg EW, Gerzoff RB, Caspersen CJ, et al. Relationship of walking to mortality among US adults with diabetes. Arch Intern Med 2003;163:1440-7.
46. Church TS, LaMonte MJ, Barlow CE, et al. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med 2005;165:2114-20.
47. Harris SB, Petrella RJ, Leadbetter W. Lifestyle interventions for type 2 diabetes. Relevance for clinical practice. Can Fam Physician 2003;49:1618-25.
48. Petrella RJ, Koval JJ, Cunningham DA, et al. Can primary care doctors prescribe exercise to improve fitness? The Step Test Exercise Prescription (STEP) project. Am J Prev Med 2003;24:316-22.
49. Kirk A, Mutrie N, MacIntyre P, et al. Effects of a 12-month physical activity counselling intervention on glycaemic control and on the status of cardiovascular risk factors in people with Type 2 diabetes. Diabetologia 2004;47:821-32.
50. Wolf AM, Conaway MR, Crowther JQ, et al. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care 2004;27:1570-6.
51. Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005; (2):CD004095.
52. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
53. Feldman R. Simplified Therapeutic Intervention to Control Hypertension (STITCH) Trial. Final results. 2007 American Heart Association Meeting; 2007 Nov 8; Orlando (Flordia).